GB876027A - New vaccines and a process for their manufacture - Google Patents

New vaccines and a process for their manufacture

Info

Publication number
GB876027A
GB876027A GB8863/58A GB886358A GB876027A GB 876027 A GB876027 A GB 876027A GB 8863/58 A GB8863/58 A GB 8863/58A GB 886358 A GB886358 A GB 886358A GB 876027 A GB876027 A GB 876027A
Authority
GB
United Kingdom
Prior art keywords
virus
vaccines
metal oxide
antigen
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB8863/58A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB876027A publication Critical patent/GB876027A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Depot vaccines comprising an antigen absorbed on a metal oxide are made by mixing (a) an antigen consisting of a virus, a bacterial antigen, a toxin produced by bacteria or an inactivation product of any of these, (b) a finely-divided metal oxide which is non-injurious to human and animal tissue and possesses a molar surface area of about 40,000 to 80,000 square metres, (c) buffering and isotonicizing substances, (d) water, and optionally (e) substances for raising the viscosity of the vaccine for example gelatine. The proportions of the ingredients are so chosen that the mixture contains per ml. about 106 to 109 virus or bacterial particles or the equivalent quantity of toxin or toxoid, and a quantity of metal oxide corresponding to a surface area of about 2 to 20 square metres. The mixture is thoroughly agitated for about 20 to 40 minutes at a temperature of about 0 DEG to 30 DEG C. The vaccines may be cautiously dehydrated, preferably by lyophilization to give stable dry preparations which can be readily reconverted into vaccines by recombination with the previously removal liquid medium and shaking for a short time. Examples given of (a) antigens are: all strains of influenza virus, strains A/Asia/1/57, PR8, B/Berlin/7/57, A1/England/19/55, A1/Dutch/56 being specifically mentioned, mumps virus strain "Enders," poliomyelitis virus, foot and mouth disease virus, viruses of the ECHO group, viruses of the coxsackie group, measles virus; bacterial antigens of B.Salmonella typhi, B.Erysipelas, B.Brucella Abortis Bang., B.Hemophilus Pertusses, B.Tuberculosis; the toxins and toxoids derived from B.Diphtheri Haemopholis, B. Tetani; of (b) metal oxides; those of aluminium, zirconium, magnesium, iron; of (c) additional agents; sodium chloride, primary potassium phosphate, secondary sodium phosphate.
GB8863/58A 1957-03-19 1958-03-19 New vaccines and a process for their manufacture Expired GB876027A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DED25189A DE1041647B (en) 1957-03-19 1957-03-19 Process for the production of depot vaccines which are in adsorption equilibrium

Publications (1)

Publication Number Publication Date
GB876027A true GB876027A (en) 1961-08-30

Family

ID=7038445

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8863/58A Expired GB876027A (en) 1957-03-19 1958-03-19 New vaccines and a process for their manufacture

Country Status (4)

Country Link
BE (1) BE565793A (en)
DE (1) DE1041647B (en)
GB (1) GB876027A (en)
SE (1) SE314164B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470067A (en) * 1967-09-19 1969-09-30 Pfizer & Co C Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes
EP1361859A1 (en) * 2001-02-15 2003-11-19 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
FR2854803A1 (en) * 2003-05-16 2004-11-19 Aventis Pasteur Composition for treating tetanus, diphtheria and poliomyelitis, comprises vaccine antigen and adjuvant comprising iron phosphate

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19511276C2 (en) * 1995-03-27 1999-02-18 Immuno Ag Adjuvant based on colloidal iron compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE885466C (en) * 1951-09-22 1953-08-06 Byk Gulden Lomberg Chem Fab Process for the preparation of a vaccine against sleeping sickness

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470067A (en) * 1967-09-19 1969-09-30 Pfizer & Co C Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes
EP1361859A1 (en) * 2001-02-15 2003-11-19 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1361859A4 (en) * 2001-02-15 2009-05-20 Kos Life Sciences Inc Modulated release particles for aerosol delivery
FR2854803A1 (en) * 2003-05-16 2004-11-19 Aventis Pasteur Composition for treating tetanus, diphtheria and poliomyelitis, comprises vaccine antigen and adjuvant comprising iron phosphate
WO2004103408A2 (en) * 2003-05-16 2004-12-02 Sanofi Pasteur Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
WO2004103408A3 (en) * 2003-05-16 2005-03-17 Aventis Pasteur Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
JP2006528958A (en) * 2003-05-16 2006-12-28 サノフィ・パスツール Vaccine composition comprising iron phosphate as vaccine adjuvant

Also Published As

Publication number Publication date
BE565793A (en) 1900-01-01
SE314164B (en) 1969-09-01
DE1041647B (en) 1958-10-23

Similar Documents

Publication Publication Date Title
Chandran et al. Development of a recombinant epsilon toxoid vaccine against enterotoxemia and its use as a combination vaccine with live attenuated sheep pox virus against enterotoxemia and sheep pox
JPH01230532A (en) Novel vaccine and its production
Jin et al. Immune responses induced by recombinant Lactobacillus plantarum expressing the spike protein derived from transmissible gastroenteritis virus in piglets
Vershilova The use of live vaccine for vaccination of human beings against brucellosis in the USSR
CN1062770C (en) Vaccine both for hepatitis A and measles and production method therefor
Cate et al. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence
GB1256456A (en) Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations
Spradbrow et al. Recent isolates of Newcastle disease virus in Australia
GB876027A (en) New vaccines and a process for their manufacture
CN1059471A (en) Heamophilus paragallinarum vaccine
CN103656660B (en) A kind of animal heat-resisting lyophilized protecting agent of live vaccine, its preparation method and application
Meyer et al. Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffkine and freeze-dried plague vaccine
US3178350A (en) Biologic antigens adjuvanted with a colloidally water-soluble polymer of acrylic acidcrosslinked with polyallyl sucrose or polyallyl pentaerythritol
GB1256457A (en) Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation
Eidson et al. Vaccination of broiler chicks from breeder flocks immunized with a live or inactivated oil emulsion Newcastle disease vaccine
GB1461188A (en) Live influenza virus vaccines and preparation thereof
Myint et al. Possible method for the production of a Covid-19 vaccine
Stashak et al. The serum antibody response to bacteriophage ΦX174 in germ-free and conventionally reared mice: I. Assay of neutralizing antibody by a 50 per cent neutralization method
US3318775A (en) Production of viral antigens with n-acetyl-ethyleneimine
Schieble et al. Antigenic variation of rhinovirus type 22
Stalheim Viable, avirulent Leptospira interrogans serotype pomona vaccine: Preservation in liquid nitrogen
Rappaport et al. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen
Coggins et al. Serological Comparison with Rabbit Antisera of Hog Cholera Virus and Bovine Virus Diarrhea Virus.
US3577524A (en) Dimethylpolysiloxane suspensions of biologics and preparation thereof
CA1193565A (en) Method of preparing an immunogen of pasteurella multocida